Literature DB >> 32369285

A Trial of Lopinavir-Ritonavir in Covid-19.

Alberto Carmona-Bayonas1, Paula Jimenez-Fonseca2, Eduardo Castañón3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32369285     DOI： 10.1056/NEJMc2008043

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.

Authors:  Cirino Botta; Alessia Indrieri; Eugenio Garofalo; Flavia Biamonte; Andrea Bruni; Pino Pasqua; Francesco Cesario; Francesco Saverio Costanzo; Federico Longhini; Francesco Mendicino
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

2.  Learning in times of stress: Lessons from COVID-19 that will last throughout this century.

Authors:  Paula Jiménez-Fonseca; Ramón Salazar; Vicent Valentí; Alberto Carmona-Bayonas; Giancarlo Agnelli
Journal:  Eur J Intern Med       Date:  2021-11-12       Impact factor: 4.487

Review 3.  COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays.

Authors:  Xueqing Wang; Yuanfang Guan
Journal:  Med Res Rev       Date:  2020-08-30       Impact factor: 12.944

4.  Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019.

Authors:  Jiaxing Zhang; Yiling Lu; Joey Sum-Wing Kwong; Xiaosi Li; Wenyi Zheng; Rui He
Journal:  Front Pharmacol       Date:  2020-08-27       Impact factor: 5.810

5.  Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.

Authors:  Jean Claude Alvarez; Pierre Moine; Benjamin Davido; Isabelle Etting; Djillali Annane; Islam Amine Larabi; Nicolas Simon
Journal:  Eur J Clin Pharmacol       Date:  2020-10-13       Impact factor: 2.953

6.  Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.

Authors:  Thais G Moreira; Kimble T F Matos; Giovana S De Paula; Thais M M Santana; Raquel G Da Mata; Fernando C Pansera; Andre S Cortina; Marcelle G Spinola; Clare M Baecher-Allan; Gerson D Keppeke; Jules Jacob; Vaseem Palejwala; Karen Chen; Saef Izzy; Brian C Healey; Rafael M Rezende; Rogerio A Dedivitis; Kunwar Shailubhai; Howard L Weiner
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.